Chris Gibson, PhD, is the Co-Founder and CEO of Recursion Pharmaceuticals, a biotech company leveraging the latest in automation, artificial intelligence and biology to do drug discovery at scale. Chris developed the technology and approach underlying Recursion as part of his MD/PhD graduate work in the lab of Co-Founder Dr. Dean Li at the University of Utah. Chris left medical school to transform this technology into the rapidly growing company it is today. Chris is a graduate of Rice University with degrees in bioengineering and managerial studies, as well as a graduate of an intense entrepreneurship course at Stanford GSB. He is a Board Member of CureHHT, a patient advocacy group for Hereditary Hemorrhagic Telangiectasia, and a member of the Rare and Undiagnosed Network Advisory Board. Outside of work, Chris enjoys cycling on both the road and the trails that cut through Utah’s great wilderness, as well as spending time with family.